MIMETAS and Partners Launch World’s First Microphysiological Systems Industry Alliance

Leiden (NL), February 10, 2025 – Today marks an important step for the globalmicrophysiological systems (MPS) field with the launch ofIAMPS – the Industry Alliance for Microphysiological Systems – the world’sfirst industry association dedicated to advancing MPS technologies. WithMIMETAS as a founding member, IAMPS brings together nine pioneering companies –AlveoliX (Switzerland), BiomimX (Italy), chiron (Netherlands), Dynamic42(Germany), InSphero (Switzerland), MIMETAS (Netherlands), NETRI (France),React4Life (Italy), and TissUse (Germany) – forming a strong coalition of innovators in organoids,organs-on-chips, and next generation human biology platforms. Thesetechnologies provide more predictive, ethical, and scalable alternatives totraditional animal and 2D models, accelerating drug development and supportingthe global shift toward human-relevant science.

IAMPS will work proactively to advanceregulatory acceptance, accelerate qualification and standardization, strengthenEuropean biobanking and tissue access, and contribute to strategic EUinvestment. Together these activities supportthe scaling of the MPS field and broader adoption by regulators and industry.

The alliance is led by Thibault Honegger(NETRI), President of IAMPS, Paola Occhetta (BiomimX), Vice‑President forRegulatory Adoption, and Jos Joore, CEO of MIMETAS and Vice‑President forLegislation and Programmes at IAMPS.

Jos Joore commented: “Microphysiologicalsystems are becoming essential to the future of drug development: human‑relevant,scalable, and transforming how therapies are discovered and evaluated. Thistechnology was pioneered in Europe, and IAMPS provides a platform to helpshape its global trajectory. By uniting leading innovators across the field, wecan drive harmonized standards and deliver the scientific rigor needed to makeMPS the worldwide norm for safe, fast, and effective drug development.”